Show Notes
The cannabis industry is experiencing rapid growth, but a deceptive practice known as "lab shopping" threatens to undermine its integrity. This episode explores how producers manipulate testing results to boost profits, the risks it poses to consumers and the measures being taken to ensure accurate labeling and product safety. Key Discussion Points:
What is Lab Shopping? The episode will define “lab shopping," explaining how cannabis producers strategically select testing labs to obtain the most favorable results, often inflating THC levels or concealing contaminants, which hurts both honest businesses and consumers.
The Impact on Consumers: Discover how inaccurate labels resulting from lab shopping can mislead consumers about THC content and product safety. For medical cannabis patients, this misinformation can lead to ineffective treatment or even harmful experiences.
The Importance of Cannabis Testing: Testing should ensure safety by checking for contaminants, and verify content. Labs test for potency, microbial contamination, pesticide residues, heavy metals, residual solvents, mycotoxins, and terpenes.
Legitimate Variations vs. Intentional Fraud: While natural variations in cannabis plants and different testing methods can cause results to vary, the episode will highlight how intentional fraud and manipulation of samples poses a significant problem.
How to Protect Yourself: Learn practical steps consumers can take to protect themselves from lab shopping, including how to understand and interpret Certificates of Analysis (COAs), look beyond THC percentages, and properly store cannabis products. When reviewing a COA, make sure it is accredited, that the batch number matches the product, and that the testing date is recent.
Regulatory Efforts: The episode will examine the actions regulators are taking to combat lab shopping, such as standardizing testing protocols, implementing secondary testing programs, and increasing oversight of testing facilities.
The Role of Consumer Education: Explore the importance of educating consumers on how to interpret COAs and the value of purchasing cannabis products from licensed and reputable dispensaries.
Accountability and Penalties: The episode will emphasize the need for strict penalties for fraudulent labs and cultivators, ensuring that those who prioritize profit over public health are held accountable.
The Path Forward: The legal cannabis industry must value safety and integrity by demanding transparency, supporting ethical businesses, and staying informed, to prioritize consumer safety, product quality, and scientific integrity.
More from Policy, Decoded
An eighth of cannabis costs $15 in Washington and $52 in Kentucky, where every buyer is a patient. A bottle of bourbon costs about the same in all fifty states. We run the experiment the other way and ask what happens if bourbon can't cross a state line, then follow four states that never traded a gram to the same $18 price. We look at who pays in an open market and who pays under a cap. The former regulator's bottom line: most of what a state charges above $18 is a decision somebody made.
🎙️ Powered by THC Group, Policy, Decoded steps back from the churn to unpack one policy story shaping cannabis, hemp, alcohol, and regulated markets. This week: on the drive to a dispensary you pass plate readers at the pharmacy, the bank, and the hardware store, and the only one any government required is the one pointed at people buying cannabis. We say plainly where we land, and it implicates us to say it: we wrote those camera rules, we would write most of them again, and we never wrote the sentence about who gets to search the footage. So we walk a Wisconsin criminal complaint that treated a lawful trip to Michigan as grounds for suspicion, the Illinois statute that banned out-of-state queries and forgot the penalty, and a Texas search that reached more than eighty thousand cameras and left a record only because a company keeps an audit log by choice. We run last week's product announcement against the Wisconsin case and watch it pass every new control. And we trace the Massachusetts rule that already got this right for one narrow class of footage, and the doorstep reasoning that says it should reach further. The former regulator's bottom line: the requirement was never the mistake, and leaving it where it sits would be. 🔗 Read the Sunday editorial This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight. Sign up to receive Policy, Decoded in your inbox
🎙️ Powered by THC Group, Policy, Decoded steps back from the churn to unpack one policy story shaping cannabis, hemp, alcohol, and regulated markets. This week: the Senate tabled the hemp amendment at two in the morning, an entire market got a crash course in civics on the way out, and fire drills only reward the people who practiced. We say plainly where we land, and it costs us something to say: the most effective advocate is the person actually affected, almost never the professional, and this publication is paid to be the professional. So we unpack a career spent on the receiving end of lobbying, the survey in which nearly nine in ten career EPA staff admitted a story moved them, the eighty percent of federal dockets that draw ten comments or fewer, and the Colorado rulemaking where hearing testimony ranked dead last because the rules were settled months earlier in workgroups. We trace Tip O'Neill's neighbor who wanted to be asked, and the North Carolina hemp businesses who watched their own senator lead the charge against them. The former regulator's bottom line: the quiet years are where the leverage lives, and you are the one a policymaker will remember. 🔗 The Power of Presence: A Guide to Policy Advocacy This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight. Sign up to receive Policy, Decoded delivered daily to your inbox.
🎙️ Powered by THC Group, Policy, Decoded steps back from the churn to unpack one policy story shaping cannabis, hemp, alcohol, and regulated markets. This week: the DEA's rescheduling hearing is over, the evidence is in, and the file it produced will matter longer than the headlines about it. For two and a half weeks, in a sealed hearing room with no cameras and a handful of public seats, the government argued under oath that cannabis belongs in Schedule III, and seven designated opponents argued back. We read the file the way a former regulator would. A government case that reversed fifty years of institutional position in a single morning, on the record for good. An opposition that put DEA's own scientist on the stand and watched its marquee witness concede the statutory question in a five-minute cross. And the 1988 precedent every operator should know: the judge who read the record most closely lost to the administrator who signed the order. The recommended decision is advice, the transcript is the document, and the real audience sits at the D.C. Circuit. The people who built this industry did their part without a hearing. The least the process can do is finish. 🔗 Read the Sunday editorial This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight. Sign up for Policy, Decoded.
🎙️ Powered by THC Group, Policy, Decoded steps back from the churn to unpack one policy story shaping cannabis, hemp, alcohol, and regulated markets. This week: after fifty years of calling cannabis dangerous and useless, the federal government has to stand up in a courtroom and argue the opposite, and the reform is overdue, right, and far easier to lose than anyone wants to admit. For fifty years the federal case against cannabis fit in a single sentence: dangerous, useless, Schedule I, filed next to heroin. On Monday, in a hearing room in Arlington, the same government has to prove the reverse, that the plant is medicine. We say plainly where we land. It is right, and it is fifty years overdue. The question is not whether it happens. It is whether the government can do the overdue thing without losing it on a technicality, or breaking the people who built the industry on the way in. So we unpack what the hearing actually is, dull administrative procedure, stacked with only opponents, deciding nothing by itself, and where the real fight has already gone, across the river to the D.C. Circuit, where April's medical reschedule is under challenge for the very shortcut that made it fast. We trace the shockwave already loose in the market, medical now in Schedule III and adult-use still in Schedule I, a fault line cutting through the same companies, the same shelves, the same customers. And we land where the rule never will, on the budtender, the grower, and the family that signed a personal guarantee, the people a Schedule III order will reach and never name. The former regulator's bottom line: a decision you cannot defend on appeal is just a reversal with a delay on it, and the fastest way to lose this reform is to win it badly. 🔗 Read the Sunday editorial This podcast may include content written or produced with the support of AI tools under human direction and editorial oversight. Sign up for Policy, Decoded.